Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Interleukin-3 Receptor Subunit Alpha Positive”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Early research (Phase 1)Looking for participantsNCT06498973
What this trial is testing

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 43
Very early researchNot Yet RecruitingNCT04599543
What this trial is testing

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Zhejiang University 36
Testing effectiveness (Phase 2)Looking for participantsNCT06561152
What this trial is testing

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University 20
Testing effectiveness (Phase 2)Ended earlyNCT05032183
What this trial is testing

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Who this might be right for
Recurrent Adult Lymphoblastic LymphomaRecurrent B Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic Leukemia+3 more
M.D. Anderson Cancer Center 4
Early research (Phase 1)Ended earlyNCT04230265
What this trial is testing

Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)
AvenCell Europe GmbH 32
Early research (Phase 1)Looking for participantsNCT05949125
What this trial is testing

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
AvenCell Europe GmbH 80
Very early researchLooking for participantsNCT06201247
What this trial is testing

Off-the-shelf CD123 CAR-NK for R/R AML

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Peking University People's Hospital 12
Very early researchUnknownNCT05574608
What this trial is testing

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia Recurrent
Affiliated Hospital to Academy of Military Medical Sciences 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03386513
What this trial is testing

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
AbbVie 179
Early research (Phase 1)Active Not RecruitingNCT02159495
What this trial is testing

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Adult Acute Myeloid Leukemia in RemissionAcute Biphenotypic LeukemiaEarly Relapse of Acute Myeloid Leukemia+10 more
City of Hope Medical Center 31
Early research (Phase 1)Study completedNCT04681105
What this trial is testing

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Who this might be right for
Recurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm+14 more
City of Hope Medical Center 13
Testing effectiveness (Phase 2)Study completedNCT06179511
What this trial is testing

Study of AZD9829 in CD123+ Hematological Malignancies

Who this might be right for
Hematological Malignancies
AstraZeneca 56
Testing effectiveness (Phase 2)WithdrawnNCT03739606
What this trial is testing

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Who this might be right for
Acute Biphenotypic LeukemiaAcute LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center
Early research (Phase 1)Ended earlyNCT05817058
What this trial is testing

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Affimed GmbH 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04086264
What this trial is testing

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
AbbVie 218